Compare Abeona Therapeutics Inc (ABEO) vs Medtronic PLC (MDT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Medtronic PLC — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Medtronic PLC trades at $82.23 (market cap $107.31B). The key difference: Medtronic PLC is far larger — about 287.4× Abeona Therapeutics Inc's market cap, and Medtronic PLC pays a 3.44% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | MDT | |
|---|---|---|
Market Cap | $373.32M | $107.31B |
Sector | Health | Health |
52-Week High | $7.23 | $105.35 |
52-Week Low | $4.17 | $73.75 |
Enterprise Value | $228.22M | $126.05B |
Dividend Yield | — | 3.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Medtronic (MDT) trades at $83.83, up 0.77% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company shows improving fundamentals with 2025 revenue of $33.54B and net income of $4.66B, supported by a 13.2% net margin. Recent acquisition of Scientia Vascular enhances its neurovascular portfolio, while analyst consensus remains strongly positive with a $98.77 price target.
MDT presents a compelling investment case with steady growth, a 3.5% dividend yield, and undervaluation relative to analyst targets. Key risks include rising debt levels and margin pressures from tariffs. The stock's current position near support levels offers a potential entry point for long-term investors seeking healthcare sector exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
